Kesler Norman & Wride’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Kesler Norman & Wride’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$445K	Buy	+4,490	New	+$405K	0.07%	209

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Kesler Norman & Wride's IHE Position: Q2 2026 in Review

Kesler Norman & Wride opened a new position in iShares US Pharmaceuticals ETF (IHE) in Q2 2026: 4,490 shares worth $445K. The stake represents 0.07% of the portfolio and ranks #209 among its holdings.

209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Kesler Norman & Wride held 4,490 shares of iShares US Pharmaceuticals ETF worth $445K as of Q2 2026.
iShares US Pharmaceuticals ETF was a new Kesler Norman & Wride position in Q2 2026.
iShares US Pharmaceuticals ETF made up 0.07% of Kesler Norman & Wride's portfolio in Q2 2026, its #209 holding.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Kesler Norman & Wride's 13F filing for Q2 2026, filed 23 Jul 2026.